Canada· CA-DIN-02543605
NURTEC ODT
A rimegepant product containing rimegepant (rimegepant sulfate), registered in Canada by PFIZER CANADA ULC. The same ATC class is registered in 16 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Rimegepant is registered in 16 of 19 countries.
Countries holding a registration under ATC N02CD06 (rimegepant), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 11 of them publish a price we can compare per daily dose
Rimegepant · ATC N02CD06
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of rimegepant costs, country by country.
Normalised to the WHO defined daily dose (37.5 mg), the median price runs from $14.84 in Switzerland to $64.33 in United States — a ×4.3 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Rimegepant · price per daily dose (37.5 mg)
USD · FX 28 Sept 2026
- US United States$64.33 (acquisition cost)
- IT Italy$18.89
- ES Spain$16.29
- CH Switzerland$14.84
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- RIMEGEPANT (RIMEGEPANT SULFATE)
- Manufacturer
- PFIZER CANADA ULC
- Country
- Canada (CA)
- ATC code
- N02CD06
- ATC class
- Rimegepant
- Defined daily dose
- 37.5 mg, O
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
90 interactions on record for rimegepant.
Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rimegepant · interactions on record
90 records
- 9 severe
- 81 moderate
Most severe, free to view
- DexamethasoneH02AB02severe
- DabrafenibL01EC02severe
- LorlatinibL01ED05severe
- DabrafenibL01XE23severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Rimegepant in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesNURTEC ODTPfizer Laboratories Div Pfizer Inc
- SwitzerlandVydura 75 mg, Lyophilisat zum EinnehmenPfizer AG
- NorwayVyduraPfizer Europe MA EEIG
- CzechiaVYDURAPfizer Europe MA EEIG, Bruxelles
- ItalyVYDURA*16x1 liofilizzati OS 75 mg dose unitariaPFIZER EUROPE MA EEIG
- United KingdomVydura 75mg oral lyophilisatesPfizer Ltd
- BelgiumVydura 75 mgPfizer Europe MA
- IcelandVyduraPfizer Europe MA EEIG*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vydura
- Liechtenstein · Vydura
- Norway · Vydura
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c397f3b8-ccb6-42ea-aed4-adea3d2e3b34 GET /v1/drugs/c397f3b8-ccb6-42ea-aed4-adea3d2e3b34?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02543605",
"form": "TABLET (ORALLY DISINTEGRATING)",
"class": "Human",
"routes": [
"ORAL"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "N02CD06",
"schedule": [
"Prescription"
],
"drug_code": "103205",
"strengths": [
"75 MG"
],
"ahfs_class": null,
"substances": [
"RIMEGEPANT (RIMEGEPANT SULFATE)"
],
"product_categorization": null
}See everything about rimegepant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.